In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Activist Shareholders Complicate Buyout Math

Executive Summary

The efforts of an increasingly vocal group of activist shareholders, including Carl Icahn, Matrix Asset Advisors, Third Point, ValueAct, and Baker Brothers Advisors, to flush out the interest of strategic buyers has become compelling and increasingly commonplace.
Advertisement

Related Content

Capital Allocation In The Age Of Shareholder Activism
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2007
Reviewing Five Years of Big Pharma's Biotech Acquisitions
Reviewing Five Years of Big Pharma's Biotech Acquisitions
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED
Genzyme Breaks a Biotech Taboo: The Hostile Bid For AnorMED

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel